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We determined the antimicrobial susceptibility of 90 clinical isolates of Stenotro-
phomonas maltophilia collected in 2009 at a tertiary care hospital in Korea. Trime-
thoprim-sulfamethoxazole, minocycline, and levofloxacin were active against 
most of the isolates tested. Moxifloxacin and tigecycline were also active and hold 
promise as therapeutic options for S. maltophilia infections. 
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Stenotrophomonas maltophilia is one of several opportunistic pathogens of growing 
significance and is the third most common nonfermentative Gram-negative bacillus 
that has been isolated from clinical specimens.1-3 Differentiation between S. maltophil-
ia colonization and infection may be difficult. Despite its relatively low virulence, S. 
maltophilia can cause a wide variety of infections including bacteremia and pneumo-
nia, especially in debilitated or immunocompromised patients. Risk factors for coloni-
zation and infection include mechanical ventilation, use of central venous catheters, 
and broad-spectrum antibiotic prophylaxis and treatment.1,4
Antimicrobial susceptibility testing methods of S. maltophilia are not clearly 
standardized, and there is poor correlation between disk diffusion and agar dilution 
results for some agents.2,5 The British Society for Antimicrobial Chemotherapy 
(BSAC, version 10.2, 2011) recommends disk diffusion and dilution testing for tri-
methoprim-sulfamethoxazole only,6 while the Clinical and Laboratory Standards 
Institute (CLSI) recommends dilution testing for trimethoprim-sulfamethoxazole, 
ceftazidime, chloramphenicol, levofloxacin, minocycline, and ticarcillin-clavula-
nate, and disk diffusion testing for only trimethoprim-sulfamethoxazole, levofloxa-
cin, and minocycline.7
Infections caused by S. maltophilia are particularly difficult to manage because 
they show resistance to many classes of antimicrobial agents. However, few stud-
ies have focused on the susceptibility of S. maltophilia in Korea.8,9 The aim of this 
study was to determine the antimicrobial susceptibility of recent clinical S. malto-Hae-Sun Chung, et al.
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the six drugs recommended by CLSI, the relatively more 
active agents were trimethoprim-sulfamethoxazole, levo-
floxacin and minocycline.
Trimethoprim-sulfamethoxazole showed the lowest MIC90 
(1 μg/mL) and the isolates showed a high susceptibility rate 
of 94% to this agent. All but five isolates were inhibited at 
≤2 μg/mL. Resistance rates to trimethoprim-sulfamethoxa-
zole have been reported to vary geographically,1,2,10,11 but 
were generally less than 20%, as was also seen in this study. 
However, isolates from cystic fibrosis patients and from 
some Asian countries, such as Taiwan and Turkey, showed 
high resistance rates (31.3-100%).5,12-14 Trimethoprim-sulfa-
methoxazole alone, or in combination with other agents, is 
still considered the treatment of choice for suspected or cul-
ture-proven S. maltophilia infections.
The MIC of levofloxacin ranged from 0.25 to 16 μg/mL, 
and the MIC50 and MIC90 were 1 and 8 μg/mL, respectively. 
The resistance rate was 13%, which was slightly higher than 
the rates of 3 to 11% seen in a previous study.1 The new flu-
oroquinolone, moxifloxacin, is more active in vitro than 
ciprofloxacin and levofloxacin.4 In this study, the MIC50 
and MIC90 of moxifloxacin were 0.5 and 4 μg/mL, respec-
tively, which were two-fold lower than those of levofloxacin. 
These results indicated that moxifloxacin could be suggest-
ed as an alternative to levofloxacin. Further clinical studies are 
necessary to evaluate the effectiveness of moxifloxacin in 
treating S. maltophilia infections, as there is little data pub-
lished on the clinical efficacy of moxifloxacin.
In this study, all S. maltophilia isolates were inhibited by 
≤4 μg/mL of minocycline, and the MIC90 was 2 μg/mL, 
philia isolates from Korea.
A total of 90 non-duplicate clinical isolates of S. malto-
philia were collected during 2009 from patients at a tertiary 
care hospital in Seoul, Korea. Sources of the isolates were 
respiratory specimens (n=46), urine (n=15), blood (n=11), 
body fluid (n=9), and pus (n=9). The species were identified 
using conventional methods and/or the ATB 32GN system 
(bioMerieux, Marcy l’Etoile, France). Antimicrobial suscep-
tibility was tested by the CLSI agar dilution method.7
The antimicrobial agents used were trimethoprim and 
sulfamethoxazole (Dong Wha, Seoul, Korea), levofloxacin 
(Daiichi, Tokyo, Japan), minocycline (SK Chemicals Life 
Science, Seoul, Korea), ticarcillin and clavulanate (Dong-
A, Yongin, Korea), ceftazidime, amikacin, and gentamicin 
(Sigma Chemical, St. Louis, MO, USA), chloramphenicol 
and tetracycline (Chong Kun Dang, Seoul, Korea), moxi-
floxacin (Bayer Korea, Seoul, Korea), tigecycline (Wyeth 
Research, Pearl River, NY, USA), cefepime (Bristol-Myers 
Squibb, Syracuse, NY, USA), imipenem (Choongwae, 
Seoul, Korea), piperacillin and tazobactam (Yuhan, Seoul, 
Korea). For the combinations of ticarcillin-clavulanate and 
piperacillin-tazobactam, constant amounts of clavulanate (2 
μg/mL) and tazobactam (4 μg/mL) were added to ticarcillin 
and piperacillin, respectively. The breakpoints recommend-
ed by CLSI for S. maltophilia were applied to interpret the 
minimum inhibitory concentrations (MIC).7 Escherichia 
coli ATCC 25922 and Pseudomonas aeruginosa ATCC 
27853 were used as controls.
Table 1 shows the MICs of antimicrobial agents and the 
resistance rates of the S. maltophilia isolates tested. Among 
Table 1. Antimicrobial Activity of Various Antimicrobial Agents Tested Against S. maltophilia Using the Agar Dilution Method
Drug
MIC (μg/mL) % Susceptibility
Range 50% 90% S I R
Amikacin         4 - >128 >128 >128 - - -
Cefepime         2 - 128 64 64 - - -
Ceftazidime         2 - >128 64 >128   23    8  69 
Chloramphenicol         4 - 64 16 32   43  36  21 
Gentamicin         1 - >128 128 >128 - - -
Imipenem       16 - >128 >128 >128 - - -
Levofloxacin    0.25 - 16 1 8   81    6  13 
Minocycline    0.12 - 4 0.5 2 100    0    0 
Moxifloxacin  ≤0.06 - 16 0.5 4 - - -
Piperacillin-tazobactam       16 - >256 >256 >256 - - -
Tetracycline         8 - >128 32 32 - - -
Ticarcillin-clavulanate         2 - >256 32 256   23  44  32 
Tigecycline    0.25 - 8 1 2 - - -
Trimethoprim-sulfamethoxazole   ≤0.06 - 64 0.5 1   94    0    6 
-Not applicable. Antimicrobial Susceptibility of S. maltophilia
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which was 16 times lower than that of tetracycline. No iso-
lates were resistant to minocycline. This data was similar to 
that of Taiwan, Brazil, Spain, and the USA.5,15-17 MICs of ti-
gecycline ranged from 0.25 to 8 μg/mL, and MIC50 and 
MIC90 were 1 and 2 μg/mL, respectively, which were simi-
lar to those in other studies.1,11 The tetracycline derivatives 
minocycline and tigecycline have shown good in vitro ac-
tivity against clinical isolates of S. maltophilia; however, 
there is little clinical data to support this claim.
The isolates showed low rates of susceptibility (23-43%) 
to ceftazidime, ticarcillin-clavulanic acid and chloramphen-
icol, which were slightly higher than those in other studies.1 
In general, β-lactams and/or β-lactamase inhibitor combina-
tions show little activity against S. maltophilia, because the 
organism has a high intrinsic resistance to most penicillins 
and cephalosporins, as well as to all carbapenems.
Aminoglycosides show poor activity against S. malto-
philia because of high intrinsic resistance and, therefore, 
are not useful in monotherapy.1,4 Despite a lack of clinical 
trials, treatment of S. maltophilia infections with a combi-
nation of two or three antimicrobials has become current 
practice where trimethoprim-sulfamethoxazole therapy is 
contraindicated.
In conclusion, trimethoprim-sulfamethoxazole, minocy-
cline, and levofloxacin showed good in vitro activity against 
S. maltophilia isolates from Korea. Moxifloxacin and tige-
cycline were also active and hold promise as therapeutic 
options for S. maltophilia.
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